ATE451921T1 - Phenylindole zur behandlung von hiv - Google Patents
Phenylindole zur behandlung von hivInfo
- Publication number
- ATE451921T1 ATE451921T1 AT02723853T AT02723853T ATE451921T1 AT E451921 T1 ATE451921 T1 AT E451921T1 AT 02723853 T AT02723853 T AT 02723853T AT 02723853 T AT02723853 T AT 02723853T AT E451921 T1 ATE451921 T1 AT E451921T1
- Authority
- AT
- Austria
- Prior art keywords
- phenylindoles
- hiv
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28339301P | 2001-04-11 | 2001-04-11 | |
PCT/US2002/011736 WO2002083126A1 (en) | 2001-04-11 | 2002-04-11 | Phenylindoles for the treatment of hiv |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE451921T1 true ATE451921T1 (de) | 2010-01-15 |
Family
ID=23085844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02723853T ATE451921T1 (de) | 2001-04-11 | 2002-04-11 | Phenylindole zur behandlung von hiv |
Country Status (10)
Country | Link |
---|---|
US (3) | US6710068B2 (de) |
EP (1) | EP1390029B1 (de) |
AR (1) | AR035857A1 (de) |
AT (1) | ATE451921T1 (de) |
AU (1) | AU2002254616B2 (de) |
BR (1) | BR0208790A (de) |
CA (1) | CA2444501C (de) |
DE (1) | DE60234760D1 (de) |
TW (1) | TWI294875B (de) |
WO (1) | WO2002083126A1 (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1305313B1 (it) * | 1998-07-17 | 2001-05-04 | Colla Paolo | 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1. |
AR035857A1 (es) * | 2001-04-11 | 2004-07-21 | Novirio Pharmaceuticals Ltd | Fenilindoles; sus composiciones farmaceuticas y sus usos |
EP1545510A4 (de) * | 2002-08-07 | 2006-11-15 | Idenix Cayman Ltd | Substituierte phenylindole zur behandlung von hiv |
ATE442375T1 (de) * | 2002-10-31 | 2009-09-15 | Metabasis Therapeutics Inc | Cytarabin-monophosphate prodrugs |
EP1620407A2 (de) * | 2003-04-28 | 2006-02-01 | Idenix (Cayman) Limited | Oxopyrimidinverbindungen |
US7439268B2 (en) * | 2003-07-18 | 2008-10-21 | Idexx Laboratories | Compositions containing prodrugs of florfenicol and methods of use |
US7265148B2 (en) * | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
PL1799696T3 (pl) | 2004-09-17 | 2009-04-30 | Idenix Pharmaceuticals Inc | Fosfoindole jako inhibitory HIV |
WO2006041961A1 (en) * | 2004-10-05 | 2006-04-20 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES | Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same |
ES2314739T3 (es) | 2004-10-27 | 2009-03-16 | Janssen Pharmaceutica Nv | Derivados de indol como moduladores de receptores de progesterona. |
US7524831B2 (en) | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
UA95788C2 (en) | 2005-12-15 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Fused pyrrole derivatives |
CA2636007A1 (en) * | 2006-01-13 | 2007-07-26 | Wyeth | Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors |
MX2009003410A (es) * | 2006-09-29 | 2009-07-17 | Idenix Pharmaceuticals Inc | Fosfoindoles enantiomericamente puros como inhibidores de vih. |
CA2665007A1 (en) * | 2006-10-06 | 2008-05-08 | Merck & Co., Inc. | Non-nucleoside reverse transcriptase inhibitors |
US7550625B2 (en) * | 2007-10-19 | 2009-06-23 | Idexx Laboratories | Esters of florfenicol |
CA2704645A1 (en) * | 2007-11-09 | 2009-05-14 | The Salk Institute For Biological Studies | Non-nucleoside reverse transcriptase inhibitors |
CA2710039C (en) | 2007-12-26 | 2018-07-03 | Critical Outcome Technologies, Inc. | Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer |
CN102007100A (zh) * | 2008-02-22 | 2011-04-06 | Irm责任有限公司 | 作为gpr119活性调控剂的化合物和组合物 |
CA2730890C (en) | 2008-07-17 | 2018-05-15 | Critical Outcome Technologies Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
US8987272B2 (en) | 2010-04-01 | 2015-03-24 | Critical Outcome Technologies Inc. | Compounds and method for treatment of HIV |
EP2606031B1 (de) | 2010-08-20 | 2017-09-27 | Amira Pharmaceuticals, Inc. | Autotaxin-hemmer und anwendungen davon |
EP2508511A1 (de) * | 2011-04-07 | 2012-10-10 | Laboratoire Biodim | Inhibitoren der Virenreplikation, Verfahren zu deren Herstellung und deren therapeutische Verwendung |
US9260416B2 (en) | 2011-05-27 | 2016-02-16 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
EP3046909A4 (de) | 2013-09-17 | 2017-03-29 | Pharmakea, Inc. | Heterocyclische vinyl-autotaxin-hemmerverbindungen |
EP3046905A4 (de) | 2013-09-17 | 2017-03-22 | Pharmakea Inc. | Vinylautotaxinhemmende verbindungen |
EP3049405A4 (de) | 2013-09-26 | 2017-03-08 | Pharmakea Inc. | Autotaxin-inhibitorverbindungen |
CN105793253B (zh) | 2013-11-22 | 2019-08-23 | 法玛克亚公司 | 自分泌运动因子抑制剂化合物 |
US10449210B2 (en) | 2014-02-13 | 2019-10-22 | Ligand Pharmaceuticals Inc. | Prodrug compounds and their uses |
JP2017520545A (ja) | 2014-07-02 | 2017-07-27 | リガンド・ファーマシューティカルズ・インコーポレイテッド | プロドラッグ化合物およびそれらの使用 |
AU2016268250B2 (en) | 2015-05-27 | 2020-08-27 | Sabre Therapeutics Llc | Autotaxin inhibitors and uses thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3304019A1 (de) * | 1983-02-07 | 1984-08-09 | Kali-Chemie Pharma Gmbh, 3000 Hannover | 3-acyloxy-1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US4866084A (en) | 1987-07-17 | 1989-09-12 | Harbor Branch Oceanographic Institution, Inc. | Topsentin compounds effective against viruses and certain tumors |
GB8823693D0 (en) * | 1988-10-08 | 1988-11-16 | Hartopp R | Injector cleaning apparatus |
US5124327A (en) | 1991-09-06 | 1992-06-23 | Merck & Co., Inc. | HIV reverse transcriptase |
WO1993005020A1 (en) * | 1991-09-06 | 1993-03-18 | Merck & Co., Inc. | Indoles as inhibitors of hiv reverse transcriptase |
US5527819A (en) | 1991-09-06 | 1996-06-18 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
DE4217964A1 (de) | 1992-05-30 | 1993-12-02 | Goedecke Ag | Indolocarbazol-Imide und deren Verwendung |
US5633457A (en) * | 1992-06-05 | 1997-05-27 | Triangle Special Products | Fuel injection cleaning and testing system and apparatus |
HUT74614A (en) | 1993-02-24 | 1997-01-28 | Merck & Co Inc | Nindol derivates suitable for treatment of infection by hiv and pharmaceutical compositions containing them |
US5489685A (en) | 1994-05-12 | 1996-02-06 | Merck & Co., Ltd. | Method of synthesizing furo[2,3-b]pyridine carboxylic acid esters |
EP0711768B1 (de) | 1994-05-31 | 2002-02-13 | Mitsui Chemicals, Inc. | Benzimidazol-derivate |
US5734081A (en) | 1994-08-05 | 1998-03-31 | Warner-Lambert Company | Arylthio compounds |
CZ217697A3 (cs) | 1995-01-10 | 1998-03-18 | Smithkline Beecham S. P. A. | Indolové deriváty, kterých je možno použít pro léčení osteoporózy, způsob jejich přípravy, farmaceutický prostředek obsahující tyto deriváty a použití |
GB9614347D0 (en) | 1996-07-09 | 1996-09-04 | Smithkline Beecham Spa | Novel compounds |
US5830894A (en) | 1997-02-21 | 1998-11-03 | Viropharma Incorporated | Methods for preventing and treating pestivirus infection and associated diseases |
US5935982A (en) | 1997-02-28 | 1999-08-10 | The University Of North Carolina At Chapel Hill | Methods of treating retroviral infection and compounds useful therefor |
US20020091148A1 (en) * | 2000-09-15 | 2002-07-11 | Bamaung Nwe Y. | 3-substituted indole antiproliferative angiogenesis inhibitors |
AR035857A1 (es) * | 2001-04-11 | 2004-07-21 | Novirio Pharmaceuticals Ltd | Fenilindoles; sus composiciones farmaceuticas y sus usos |
EP1545510A4 (de) * | 2002-08-07 | 2006-11-15 | Idenix Cayman Ltd | Substituierte phenylindole zur behandlung von hiv |
US7406822B2 (en) * | 2005-06-30 | 2008-08-05 | Caterpillar Inc. | Particulate trap regeneration system and control strategy |
US7481048B2 (en) * | 2005-06-30 | 2009-01-27 | Caterpillar Inc. | Regeneration assembly |
-
2002
- 2002-04-11 AR ARP020101341A patent/AR035857A1/es unknown
- 2002-04-11 BR BR0208790-1A patent/BR0208790A/pt not_active IP Right Cessation
- 2002-04-11 WO PCT/US2002/011736 patent/WO2002083126A1/en not_active Application Discontinuation
- 2002-04-11 EP EP02723853A patent/EP1390029B1/de not_active Expired - Lifetime
- 2002-04-11 AT AT02723853T patent/ATE451921T1/de not_active IP Right Cessation
- 2002-04-11 AU AU2002254616A patent/AU2002254616B2/en not_active Ceased
- 2002-04-11 US US10/122,252 patent/US6710068B2/en not_active Expired - Lifetime
- 2002-04-11 CA CA002444501A patent/CA2444501C/en not_active Expired - Fee Related
- 2002-04-11 DE DE60234760T patent/DE60234760D1/de not_active Expired - Fee Related
- 2002-04-16 TW TW093117031A patent/TWI294875B/zh active
-
2004
- 2004-03-22 US US10/806,295 patent/US20040180888A1/en not_active Abandoned
-
2007
- 2007-07-20 US US11/880,303 patent/US20070293668A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20020193415A1 (en) | 2002-12-19 |
EP1390029A1 (de) | 2004-02-25 |
US20040180888A1 (en) | 2004-09-16 |
DE60234760D1 (de) | 2010-01-28 |
US6710068B2 (en) | 2004-03-23 |
AU2002254616B2 (en) | 2007-09-06 |
TWI294875B (en) | 2008-03-21 |
BR0208790A (pt) | 2004-03-30 |
CA2444501A1 (en) | 2002-10-24 |
TW200422291A (en) | 2004-11-01 |
AR035857A1 (es) | 2004-07-21 |
US20070293668A1 (en) | 2007-12-20 |
EP1390029B1 (de) | 2009-12-16 |
WO2002083126A1 (en) | 2002-10-24 |
EP1390029A4 (de) | 2005-11-30 |
CA2444501C (en) | 2009-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60234760D1 (de) | Phenylindole zur behandlung von hiv | |
DE60219292D1 (de) | Pyrazolderivate zur behandlung von hiv | |
DE60019556D1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
ATE265860T1 (de) | Impstoff zur behandlung von atherosclerosis | |
ATE269303T1 (de) | Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen | |
ATE275145T1 (de) | Chinazolinderivate zur behandlung von tumoren | |
DE602004028763D1 (de) | Te zur behandlung von virenerkrankungen | |
DE60019555D1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
ATE410430T1 (de) | 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose | |
DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
DE60019158D1 (de) | Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien | |
DE60204466D1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
ATE279386T1 (de) | Retinoide zur behandlung von emphysem | |
DE60238765D1 (de) | Carbamatverbindungen zur behandlung von schmerz | |
DE60214355D1 (de) | Exemestan zur behandlung von hormonabhängigen störungen | |
ATE273276T1 (de) | Cyclobutendion-derivate zur behandlung von artherosclerose | |
DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
DE60006412D1 (de) | Oxazinochinolone zur behandlung von viralen infektionen | |
DE50205466D1 (de) | Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen | |
DE60021252D1 (de) | Antikonvulsiva zur behandlung von autismus | |
DE60223707D1 (de) | Calcium-l-threonat zur behandlung von knochenfrakturen | |
DE60103685D1 (de) | Behandlung von Poriomania | |
DE50212649D1 (de) | Verwendung von desoxypeganin zur behandlung der klinischen depression | |
DE60233740D1 (de) | Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |